Chemical epigenetics to assess the role of HDAC1–3 inhibition in macrophage pro-inflammatory gene expression

Maria E. Ourailidou, Niek G. J. Leus, Kim Krist, Alessia Lenoci, Antonello Mai and Frank J. Dekker

Med. Chem. Commun., 2016, 7, 2184
DOI: 10.1039/C6MD00375C

A potent trifluoromethyl ketone histone deacetylase inhibitor exhibits class-dependent mechanism of action

Andreas S. Madsen and Christian A. Olsen

Med. Chem. Commun., 2016, 7, 464
DOI: 10.1039/C5MD00451A

Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro

Kent Algate, David Haynes, Tracy Fitzsimmons, Ornella Romeo, Florence Wagner, Edward Holson, Robert Reid, David Fairlie, Peter Bartold and Melissa Cantley

J of Cellular Biochemistry, 2020, 121, 244
DOI: 10.1002/jcb.29137

Chemogenomic analysis reveals key role for lysine acetylation in regulating Arc stability

Jasmin Lalonde, Surya A. Reis, Sudhir Sivakumaran, Carl S. Holland, Hendrik Wesseling, John F. Sauld, Begum Alural, Wen-Ning Zhao, Judith A. Steen and Stephen J. Haggarty

Nat Commun, 2017, 8
DOI: 10.1038/s41467-017-01750-7

Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors

Linda Schäker‐Hübner, Reza Haschemi, Thomas Büch, Fabian B. Kraft, Birke Brumme, Andrea Schöler, Robert Jenke, Jens Meiler, Achim Aigner, Gerd Bendas and Finn K. Hansen

ChemMedChem, 2022, 17
DOI: 10.1002/cmdc.202100755

Preclinical epigenetic models for screening epigenetic drugs for schizophrenia

Jacob Peedicayil

Journal of Pharmacological and Toxicological Methods, 2016, 77, 1
DOI: 10.1016/j.vascn.2015.09.002

Linda Schäker-Hübner and Finn K. Hansen

ACS Pharmacol. Transl. Sci., 2026, 9, 462
DOI: 10.1021/acsptsci.5c00619

Epigenetic Inhibitors as Alzheimer’s Disease Therapeutic Agents

Yasunobu Yamashita, Yukihiro Itoh, Yuri Takada and Takayoshi Suzuki

Chem. Pharm. Bull., 2024, 72, 630
DOI: 10.1248/cpb.c23-00027

Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators

Peng Zhan, Yukihiro Itoh, Takayoshi Suzuki and Xinyong Liu

J. Med. Chem., 2015, 58, 7611
DOI: 10.1021/acs.jmedchem.5b00229

Inhibitors of class I histone deacetylases attenuate thioacetamide‐induced liver fibrosis in mice by suppressing hepatic type 2 inflammation

Zhixuan Loh, Rebecca L. Fitzsimmons, Robert C. Reid, Divya Ramnath, Andrew Clouston, Praveer K. Gupta, Katharine M. Irvine, Elizabeth E. Powell, Kate Schroder, Jennifer L. Stow, Matthew J. Sweet, David P. Fairlie and Abishek Iyer

British J Pharmacology, 2019, 176, 3775
DOI: 10.1111/bph.14768

Modulation of cellular processes by histone and non-histone protein acetylation

Maria Shvedunova and Asifa Akhtar

Nat Rev Mol Cell Biol, 2022, 23, 329
DOI: 10.1038/s41580-021-00441-y

Temporal perturbation of histone deacetylase activity reveals a requirement for HDAC1–3 in mesendoderm cell differentiation

Enakshi Sinniah, Zhixuan Wu, Sophie Shen, Marina Naval-Sanchez, Xiaoli Chen, Junxian Lim, Abbigail Helfer, Abishek Iyer, Jiahui Tng, Andrew J. Lucke, Robert C. Reid, Meredith A. Redd, Christian M. Nefzger, David P. Fairlie and Nathan J. Palpant

Cell Reports, 2022, 39, 110818
DOI: 10.1016/j.celrep.2022.110818

Design, Synthesis, and In-silico Evaluation of Benzyl oxybenzoate Derivatives as Dual HDAC Inhibitors for Cancer and CNS Disorders

Dhiaa Ali Abdulkader and Monther Faisal Mahdi

AJPS, 2026, 25, 917
DOI: 10.32947/ajps.v25i5.1307

Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations

Tamara Maes, Cristina Mascaró, David Rotllant, Michele Matteo Pio Lufino, Angels Estiarte, Nathalie Guibourt, Fernando Cavalcanti, Christian Griñan-Ferré, Mercè Pallàs, Roser Nadal, Antonio Armario, Isidro Ferrer, Alberto Ortega, Nuria Valls, Matthew Fyfe, Marc Martinell, Julio César Castro Palomino, Carlos Buesa Arjol and Hoon Ryu

PLoS ONE, 2020, 15, e0233468
DOI: 10.1371/journal.pone.0233468

The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington’s Disease Mice

Katharina Hecklau, Susanne Mueller, Stefan Paul Koch, Mustafa Hussain Mehkary, Busra Kilic, Christoph Harms, Philipp Boehm-Sturm and Ferah Yildirim

Front. Mol. Neurosci., 2021, 14
DOI: 10.3389/fnmol.2021.616886

Rapid Determination of Kinetic Constants for Slow-Binding Inhibitors and Inactivators of Human Histone Deacetylase 8

Aleksandra Kopranovic and Franz-Josef Meyer-Almes

IJMS, 2024, 25, 5593
DOI: 10.3390/ijms25115593

Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors

Florence F. Wagner, Michel Weïwer, Stefan Steinbacher, Adrian Schomburg, Peter Reinemer, Jennifer P. Gale, Arthur J. Campbell, Stewart L. Fisher, Wen-Ning Zhao, Surya A. Reis, Krista M. Hennig, Méryl Thomas, Peter Müller, Martin R. Jefson, Daniel M. Fass, Stephen J. Haggarty, Yan-Ling Zhang and Edward B. Holson

Bioorganic & Medicinal Chemistry, 2016, 24, 4008
DOI: 10.1016/j.bmc.2016.06.040

Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia

Jesse J. McClure, Cheng Zhang, Elizabeth S. Inks, Yuri K. Peterson, Jiaying Li and C. James Chou

J. Med. Chem., 2016, 59, 9942
DOI: 10.1021/acs.jmedchem.6b01385

Medicinal chemistry advances in targeting class I histone deacetylases

Diaaeldin I. Abdallah, Elvin D. de Araujo, Naman H. Patel, Lina S. Hasan, Richard Moriggl, Oliver H. Krämer and Patrick T. Gunning

Exploration of Targeted Anti-tumor Therapy, 2023, 757
DOI: 10.37349/etat.2023.00166

Histone deacetylase-2 controls IL-1β production through the regulation of NLRP3 expression and activation in tuberculosis infection

Jôsimar Dornelas Moreira, Alexei Iakhiaev, Ramakrishna Vankayalapati, Bock-Gie Jung and Buka Samten

iScience, 2022, 25, 104799
DOI: 10.1016/j.isci.2022.104799

Combinatorial In Silico Strategy towards Identifying Potential Hotspots during Inhibition of Structurally Identical HDAC1 and HDAC2 Enzymes for Effective Chemotherapy against Neurological Disorders

Shabir Ahmad Ganai, Ehsaan Abdullah, Romana Rashid and Mohammad Altaf

Front. Mol. Neurosci., 2017, 10
DOI: 10.3389/fnmol.2017.00357

PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia

Tonya M. Gilbert, Nicole R. Zürcher, Christine J. Wu, Anisha Bhanot, Baileigh G. Hightower, Minhae Kim, Daniel S. Albrecht, Hsiao-Ying Wey, Frederick A. Schroeder, Anais Rodriguez-Thompson, Thomas M. Morin, Kamber L. Hart, Amelia M. Pellegrini, Misha M. Riley, Changning Wang, Steven M. Stufflebeam, Stephen J. Haggarty, Daphne J. Holt, Marco L. Loggia, Roy H. Perlis, Hannah E. Brown, Joshua L. Roffman and Jacob M. Hooker

Journal of Clinical Investigation, 2018, 129, 364
DOI: 10.1172/JCI123743

Discovery of in Vivo Chemical Probes for Treating Alzheimer’s Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors

Obdulia Rabal, Juan A. Sánchez-Arias, Mar Cuadrado-Tejedor, Irene de Miguel, Marta Pérez-González, Carolina García-Barroso, Ana Ugarte, Ander Estella-Hermoso de Mendoza, Elena Sáez, Maria Espelosin, Susana Ursua, Tan Haizhong, Wu Wei, Xu Musheng, Ana Garcia-Osta and Julen Oyarzabal

ACS Chem. Neurosci., 2019, 10, 1765
DOI: 10.1021/acschemneuro.8b00648

Epigenetic Dysregulation in Neurodegeneration: The Role of Histone Deacetylases and Emerging Inhibitor Strategies

Yogesh Pawar, Aleksandra Kopranovic, Ramaa C S and Franz-Josef Meyer-Almes

Biomolecules, 2026, 16, 103
DOI: 10.3390/biom16010103

Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue

Gavin Rumbaugh, Stephanie E Daws, Emin D Ozkan, Camilo S Rojas, Christopher R Hubbs, Massimiliano Aceti, Mark Kilgore, Shashi Kudugunti, Sathyanarayanan V Puthanveettil, J David Sweatt, James Rusche and Courtney A Miller

Neuropsychopharmacol, 2015, 40, 2307
DOI: 10.1038/npp.2015.93

Transient receptor potential vanilloid 1 antagonism in neuroinflammation, neuroprotection and epigenetic regulation: potential therapeutic implications for severe psychiatric disorders treatment

Andrea Escelsior, Bruno Sterlini, Martino Belvederi Murri, Pierluigi Valente, Andrea Amerio, Manfredo Radicati di Brozolo, Beatriz Pereira da Silva and Mario Amore

Psychiatric Genetics, 2020, 30, 39
DOI: 10.1097/YPG.0000000000000249

Targeting SIK3 to modulate hippocampal synaptic plasticity and cognitive function by regulating the transcription of HDAC4 in a mouse model of Alzheimer’s disease

Xiaoman Dai, Anlan Lin, Lvping Zhuang, Qingyong Zeng, Lili Cai, Yuanxiang Wei, Hongjie Liang, Weijie Gao, Jing Zhang and Xiaochun Chen

Neuropsychopharmacol., 2024, 49, 942
DOI: 10.1038/s41386-023-01775-1

Kinetically selective and potent inhibitors of HDAC8

Markus Schweipert, Niklas Jänsch, Wisely Oki Sugiarto and Franz-Josef Meyer-Almes

Biological Chemistry, 2019, 400, 733
DOI: 10.1515/hsz-2018-0363

Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases

Anton Frühauf and Franz-Josef Meyer-Almes

Molecules, 2021, 26, 5151
DOI: 10.3390/molecules26175151

Acetylation and deacetylation dynamics in stress response to cancer and infections

Lili Li, Yanqiong Zeng, Genhong Cheng and Heng Yang

Seminars in Immunology, 2025, 78, 101957
DOI: 10.1016/j.smim.2025.101957

Propofol exposure during early gestation impairs learning and memory in rat offspring by inhibiting the acetylation of histone

Jiamei Lin, Shengqiang Wang, Yunlin Feng, Weihong Zhao, Weilu Zhao, Foquan Luo and Namin Feng

J Cellular Molecular Medi, 2018, 22, 2600
DOI: 10.1111/jcmm.13524

Nuclear Coregulatory Complexes in Tregs as Targets to Promote Anticancer Immune Responses

Lanette M. Christensen and Wayne W. Hancock

Front. Immunol., 2022, 13
DOI: 10.3389/fimmu.2022.909816

CRISPR-mediated HDAC2 disruption identifies two distinct classes of target genes in human cells

Priyanka Somanath, Rachel Herndon Klein, Paul S. Knoepfler and Roberto Mantovani

PLoS ONE, 2017, 12, e0185627
DOI: 10.1371/journal.pone.0185627

How the epigenome integrates information and reshapes the synapse

Rianne R. Campbell and Marcelo A. Wood

Nat Rev Neurosci, 2019, 20, 133
DOI: 10.1038/s41583-019-0121-9

MHY446 induces apoptosis via reactive oxygen species-mediated endoplasmic reticulum stress in HCT116 human colorectal cancer cells

Yu Ra Ahn, Jung Yoon Jang, Yong Jung Kang, Hye Jin Oh, Min Kyung Kang, Dahye Yoon, Hyung Sik Kim, Hyung Ryong Moon, Hae Young Chung and Nam Deuk Kim

Journal of Chemotherapy, 2024, 36, 483
DOI: 10.1080/1120009X.2023.2286757

Inhibition of Histone Deacetylases 1, 2, and 3 Enhances Clearance of Cholesterol Accumulation in Niemann-Pick C1 Fibroblasts

Dana L. Cruz, Nina Pipalia, Shu Mao, Deepti Gadi, Gang Liu, Michael Grigalunas, Matthew O’Neill, Taylor R. Quinn, Andi Kipper, Andreas Ekebergh, Alexander Dimmling, Carlos Gartner, Bruce J. Melancon, Florence F. Wagner, Edward Holson, Paul Helquist, Olaf Wiest and Frederick R. Maxfield

ACS Pharmacol. Transl. Sci., 2021, 4, 1136
DOI: 10.1021/acsptsci.1c00033

Nuclear dynamics and stress responses in Alzheimer’s disease

Artemis Iatrou, Eric M. Clark and Yanling Wang

Mol Neurodegeneration, 2021, 16
DOI: 10.1186/s13024-021-00489-6

From QSAR to dynamics: A data-driven design of drug-like lactam-based HDAC inhibitors for diffuse large B-cell lymphoma

Josiah Joseph Isah, Adamu Uzairu, Sani Uba and Muhammad Tukur Ibrahim

In Silico Research in Biomedicine, 2025, 1, 100060
DOI: 10.1016/j.insi.2025.100060

Histone Deacetylase Inhibitors as Cognitive Enhancers and Modifiers of Mood and Behavior

Dilipkumar Pal, Pooja Sahu, Abhishek K. Mishra, Albert Hagelgans and Olga Sukocheva

CDT, 2023, 24, 728
DOI: 10.2174/1389450124666221207090108

Epigenetic Alterations in Alzheimer’s Disease

Jose V. Sanchez-Mut and Johannes Gräff

Front. Behav. Neurosci., 2015, 9
DOI: 10.3389/fnbeh.2015.00347

Profiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitors

Daiqing Liao

Drug Discovery Today: Technologies, 2015, 18, 24
DOI: 10.1016/j.ddtec.2015.10.006

Iryna S. Palamarchuk, George M. Slavich, Tracy Vaillancourt and Tarek K. Rajji

BMC Neurosci, 2023, 24
DOI: 10.1186/s12868-023-00831-2

Histone Deacetylase 2 in Alzheimer’s Disease: A Comprehensive Molecular Blueprint for Therapeutic Targeting

Kavuma Asadi, Radha K., Sairaj Satarker and Prasada Chowdari Gurram

Mol Neurobiol, 2025, 62, 16489
DOI: 10.1007/s12035-025-05264-y

An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection

Florence F. Wagner, Morten Lundh, Taner Kaya, Patrick McCarren, Yan-Ling Zhang, Shrikanta Chattopadhyay, Jennifer P. Gale, Thomas Galbo, Stewart L. Fisher, Bennett C. Meier, Amedeo Vetere, Sarah Richardson, Noel G. Morgan, Dan Ploug Christensen, Tamara J. Gilbert, Jacob M. Hooker, Mélanie Leroy, Deepika Walpita, Thomas Mandrup-Poulsen, Bridget K. Wagner and Edward B. Holson

ACS Chem. Biol., 2016, 11, 363
DOI: 10.1021/acschembio.5b00640

Dissecting structure–activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation

Balaram Ghosh, Wen-Ning Zhao, Surya A. Reis, Debasis Patnaik, Daniel M. Fass, Li-Huei Tsai, Ralph Mazitschek and Stephen J. Haggarty

Bioorganic & Medicinal Chemistry Letters, 2016, 26, 1265
DOI: 10.1016/j.bmcl.2016.01.022

Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor

Emiliano Tamanini, Shin Miyamura, Ildiko M. Buck, Benjamin D. Cons, Lee Dawson, Charlotte East, Takashi Futamura, Shintaro Goto, Charlotte Griffiths-Jones, Tetsuya Hashimoto, Tom D. Heightman, Shunpei Ishikawa, Hideki Ito, Yosuke Kaneko, Tatsuya Kawato, Kazumi Kondo, Naoki Kurihara, James M. McCarthy, Yukiko Mori, Tsuyoshi Nagase, Yuichiro Nakaishi, Judith Reeks, Akimasa Sato, Patrick Schöpf, Kuninori Tai, Taichi Tamai, Dominic Tisi and Alison J.-A. Woolford

ACS Med. Chem. Lett., 2022, 13, 1591
DOI: 10.1021/acsmedchemlett.2c00272

Identification of potent histone deacetylase 2 (HDAC2) inhibitors through combined structure and ligand-based designs and molecular modelling approach

Asha Anand, Powsali Ghosh, Ravi Singh, Nilesh Gajanan Bajad, Ashok Kumar and Sushil Kumar Singh

Journal of Biomolecular Structure and Dynamics, 2024, 42, 4679
DOI: 10.1080/07391102.2023.2222177

Defects in the Alternative Splicing-Dependent Regulation of REST Cause Deafness

Yoko Nakano, Michael C. Kelly, Atteeq U. Rehman, Erich T. Boger, Robert J. Morell, Matthew W. Kelley, Thomas B. Friedman and Botond Bánfi

Cell, 2018, 174, 536
DOI: 10.1016/j.cell.2018.06.004

Cellular Target Engagement and Dissociation Kinetics of Class I-Selective Histone Deacetylase (HDAC) Inhibitors

Irina Honin, Zora Novakova, Felix Feller, Simon Schneider, Linda Schäker-Hübner, Cyril Barinka and Finn K. Hansen

IJMS, 2026, 27, 3036
DOI: 10.3390/ijms27073036

Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation

Varun Dewaker, Pratik Narain Srivastava, Saroj Verma, Ajay K. Srivastava and Yenamandra S. Prabhakar

Journal of Biomolecular Structure and Dynamics, 2022, 40, 13432
DOI: 10.1080/07391102.2021.1989037

The multifunctional protein PACS-1 is required for HDAC2- and HDAC3-dependent chromatin maturation and genomic stability

Chinnadurai Mani, Kaushlendra Tripathi, Shan Luan, David W. Clark, Joel F. Andrews, Alessandro Vindigni, Gary Thomas and Komaraiah Palle

Oncogene, 2020, 39, 2583
DOI: 10.1038/s41388-020-1167-x

Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia

Walter H. Moos, Eleni Maneta, Carl A. Pinkert, Michael H. Irwin, Michelle E. Hoffman, Douglas V. Faller and Kosta Steliou

Drug Development Research, 2016, 77, 53
DOI: 10.1002/ddr.21295

Epigenetic Explorations of Neurological Disorders, the Identification Methods, and Therapeutic Avenues

Zeba Firdaus and Xiaogang Li

IJMS, 2024, 25, 11658
DOI: 10.3390/ijms252111658

Ketosis may promote brain macroautophagy by activating Sirt1 and hypoxia-inducible factor-1

Mark F. McCarty, James J. DiNicolantonio and James H. O’Keefe

Medical Hypotheses, 2015, 85, 631
DOI: 10.1016/j.mehy.2015.08.002

HAT- and HDAC-Targeted Protein Acetylation in the Occurrence and Treatment of Epilepsy

Jie Wang, Feng Yun, Jiahui Sui, Wenpeng Liang, Dingding Shen and Qi Zhang

Biomedicines, 2022, 11, 88
DOI: 10.3390/biomedicines11010088

An Evolutionarily Conserved SoxB-Hdac2 Crosstalk Regulates Neurogenesis in a Cnidarian

Hakima Flici, Christine E. Schnitzler, R. Cathriona Millane, Graham Govinden, Amy Houlihan, Stephanie D. Boomkamp, Sanbing Shen, Andreas D. Baxevanis and Uri Frank

Cell Reports, 2017, 18, 1395
DOI: 10.1016/j.celrep.2017.01.019

Discovery of Highly Selective HDAC2 Inhibitors in Cells That Elevate Histone Acetylation In Vivo without Adverse Effects from Dual Inhibition of HDAC1 and 2

Naoyuki Suzuki, Hidekuni Yamakawa, Ken Yoshihara, Kazuki Niidome, Kosuke Anan, Kenji Takaya, Kensuke Kouki, Kazuki Fujimoto, Hiroko Ono, Takaya Izumi, Kazuhiro Unemura, Mana Ito, Takuya Hatta, Yasuto Kido, Naotaka Horiguchi and Ken-ichi Kusakabe

J. Med. Chem., 2026, 69, 6429
DOI: 10.1021/acs.jmedchem.5c02022

Epigenetic Regulation in Schizophrenia: Focus on Methylation and Histone Modifications in Human Studies

Natasha Delphin, Caitlin Aust, Lyn Griffiths and Francesca Fernandez

Genes, 2024, 15, 272
DOI: 10.3390/genes15030272

Advances toward precision medicine for bipolar disorder: mechanisms & molecules

Stephen J. Haggarty, Rakesh Karmacharya and Roy H. Perlis

Mol Psychiatry, 2021, 26, 168
DOI: 10.1038/s41380-020-0831-4

Progress in the Research of Selective Histone deacetylase Inhibitors

立园张

AMC, 2021, 09, 9
DOI: 10.12677/AMC.2021.91002

Dengue and Psychiatry: Manifestations, Mechanisms, and Management Options

Damodharan Dinakaran, Vanteemar S Sreeraj and Ganesan Venkatasubramanian

Indian Journal of Psychological Medicine, 2022, 44, 429
DOI: 10.1177/02537176211022571

Histone H3K9 Trimethylation Downregulates the Expression of Brain-Derived Neurotrophic Factor in the Dorsal Hippocampus and Impairs Memory Formation During Anaesthesia and Surgery

Tong Wu, Xiao-Yu Sun, Xiu Yang, Le Liu, Kun Tong, Ya Gao, Jing-Ru Hao, Jing Cao and Can Gao

Front. Mol. Neurosci., 2019, 12
DOI: 10.3389/fnmol.2019.00246

Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD)

Erika Bourguet, Katarzyna Ozdarska, Gautier Moroy, Jérôme Jeanblanc and Mickaël Naassila

J. Med. Chem., 2018, 61, 1745
DOI: 10.1021/acs.jmedchem.7b00115

A translational perspective on histone acetylation modulators in psychiatric disorders

Surajit Ganguly and Subhendu Seth

Psychopharmacology, 2018, 235, 1867
DOI: 10.1007/s00213-018-4947-z

Zinc-Dependent Histone Deacetylase (HDAC) Inhibitors: Therapeutic Potential, Pharmacophore Structure, and Methods for Testing Deacylase Activity

A. S. Zemskaya, S. N. Kochetkov and M. V. Kozlov

Mol Biol, 2025, 59, 668
DOI: 10.1134/S002689332570027X

On-rate based optimization of structure–kinetic relationship – surfing the kinetic map

Andreas Schoop and Fabian Dey

Drug Discovery Today: Technologies, 2015, 17, 9
DOI: 10.1016/j.ddtec.2015.08.003

Inflammation‐mediated deacetylation of the ribonuclease 1 promoter via histone deacetylase 2 in endothelial cells

Katrin Bedenbender, Nicoletta Scheller, Silvia Fischer, Silke Leiting, Klaus T. Preissner, Bernd T. Schmeck and Evelyn Vollmeister

The FASEB Journal, 2019, 33, 9017
DOI: 10.1096/fj.201900451R

A neuronal cell-based reporter system for monitoring the activity of HDAC2

Kazuhiro Unemura, Masako Kawano, Mai Takakura, Ikuko Iwata, Kana Hyakkoku, Naotaka Horiguchi, Tomohiko Okuda and Yukinori Hirano

SLAS Discovery, 2022, 27, 440
DOI: 10.1016/j.slasd.2022.10.001

Maternal Exposure of Rats to Isoflurane during Late Pregnancy Impairs Spatial Learning and Memory in the Offspring by Up-Regulating the Expression of Histone Deacetylase 2

Foquan Luo, Yan Hu, Weilu Zhao, Zhiyi Zuo, Qi Yu, Zhiyi Liu, Jiamei Lin, Yunlin Feng, Binda Li, Liuqin Wu, Lin Xu and Huafeng Wei

PLoS ONE, 2016, 11, e0160826
DOI: 10.1371/journal.pone.0160826

Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy

Manasa Gangadhar Shetty, Padmini Pai, Renita Esther Deaver, Kapaettu Satyamoorthy and Kampa Sundara Babitha

Pharmacological Research, 2021, 170, 105695
DOI: 10.1016/j.phrs.2021.105695

Evolution of Slow-Binding Inhibitors Targeting Histone Deacetylase Isoforms

Anirban Mukherjee, Farzad Zamani and Takayoshi Suzuki

J. Med. Chem., 2023, 66, 11672
DOI: 10.1021/acs.jmedchem.3c01160

Acan downregulation in parvalbumin GABAergic cells reduces spontaneous recovery of fear memories

Marisol Lavertu-Jolin, Bidisha Chattopadhyaya, Pegah Chehrazi, Denise Carrier, Florian Wünnemann, Séverine Leclerc, Félix Dumouchel, Derek Robertson, Hicham Affia, Kamal Saba, Vijaya Gopal, Anant Bahadur Patel, Gregor Andelfinger, Graçiela Pineyro and Graziella Di Cristo

Mol Psychiatry, 2023, 28, 2946
DOI: 10.1038/s41380-023-02085-0

Histone Deacetylases and Their Isoform-Specific Inhibitors in Ischemic Stroke

Svetlana Demyanenko, Valentina Dzreyan and Svetlana Sharifulina

Biomedicines, 2021, 9, 1445
DOI: 10.3390/biomedicines9101445

Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy

Jose A. Muñoz-Moreno, Sara Carrillo-Molina, Ignacio Martínez-Zalacaín, Cristina Miranda, Christian Manzardo, Pep Coll, Michael Meulbroek, Tomáš Hanke, Maite Garolera, Josep M. Miró, Christian Brander, Bonaventura Clotet, Carles Soriano-Mas, José Moltó and Beatriz Mothe

AIDS, 2022, 36, 363
DOI: 10.1097/QAD.0000000000003121

Emerging approaches for histone deacetylase inhibitor drug discovery

Clemens Zwergel, Sergio Valente, Claus Jacob and Antonello Mai

Expert Opinion on Drug Discovery, 2015, 10, 599
DOI: 10.1517/17460441.2015.1038236

Genome-wide screening identifies Polycomb repressive complex 1.3 as an essential regulator of human naïve pluripotent cell reprogramming

Amanda J. Collier, Adam Bendall, Charlene Fabian, Andrew A. Malcolm, Katarzyna Tilgner, Claudia I. Semprich, Katarzyna Wojdyla, Paola Serena Nisi, Kamal Kishore, Valar Nila Roamio Franklin, Bahar Mirshekar-Syahkal, Clive D’Santos, Kathrin Plath, Kosuke Yusa and Peter J. Rugg-Gunn

Sci. Adv., 2022, 8
DOI: 10.1126/sciadv.abk0013

HDAC2 targeting stabilizes the CoREST complex in renal tubular cells and protects against renal ischemia/reperfusion injury

David D. Aufhauser, Paul Hernandez, Seth J. Concors, Ciaran O’Brien, Zhonglin Wang, Douglas R. Murken, Arabinda Samanta, Ulf H. Beier, Lauren Krumeich, Tricia R. Bhatti, Yanfeng Wang, Guanghui Ge, Liqing Wang, Shayan Cheraghlou, Florence F. Wagner, Edward B. Holson, Jay H. Kalin, Philip A. Cole, Wayne W. Hancock and Matthew H. Levine

Sci Rep, 2021, 11
DOI: 10.1038/s41598-021-88242-3

Targeted Gene Repression Using Novel Bifunctional Molecules to Harness Endogenous Histone Deacetylation Activity

Kyle V. Butler, Anna M. Chiarella, Jian Jin and Nathaniel A. Hathaway

ACS Synth. Biol., 2018, 7, 38
DOI: 10.1021/acssynbio.7b00295

Resilience as a translational endpoint in the treatment of PTSD

Gopalkumar Rakesh, Rajendra A. Morey, Anthony S. Zannas, Zainab Malik, Christine E. Marx, Ashley N. Clausen, Michael D. Kritzer and Steven T. Szabo

Mol Psychiatry, 2019, 24, 1268
DOI: 10.1038/s41380-019-0383-7

Valproic acid ameliorates cauda equina injury by suppressing HDAC2‐mediated ferroptosis

Qingjie Kong, Fudong Li, Kaiqiang Sun, Xiaofei Sun and Jun Ma

CNS Neurosci Ther, 2024, 30
DOI: 10.1111/cns.14524

Epigenetic reprogramming of HDAC2 in CA1 excitatory neurons determines Pb-induced non-spatial memory deficits

Mengmeng Wang, Chengqing Huang, Shu Ai, Yanzhou Xia, Changqing Li, Yuxuan Zhi, Kun Wang, Ming Nie, Xiaozhen Gu, Yi Xu, Heyujia Zhang and Hui-Li Wang

Journal of Hazardous Materials, 2025, 495, 138818
DOI: 10.1016/j.jhazmat.2025.138818

Kinetic binding assays for the analysis of protein–ligand interactions

Franz-Josef Meyer-Almes

Drug Discovery Today: Technologies, 2015, 17, 1
DOI: 10.1016/j.ddtec.2015.08.004

Dysregulation of EAAT2 and VGLUT2 Spinal Glutamate Transports via Histone Deacetylase 2 (HDAC2) Contributes to Paclitaxel-induced Painful Neuropathy

Xiao-Min Wang, Pan Gu, Leorey Saligan, Michael Iadarola, Stanley Sau Ching Wong, Lian Kah Ti and Chi Wai Cheung

Molecular Cancer Therapeutics, 2020, 19, 2196
DOI: 10.1158/1535-7163.MCT-20-0006

Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders

Piyush Gediya, Palak K. Parikh, Vivek K. Vyas and Manjunath D. Ghate

European Journal of Medicinal Chemistry, 2021, 216, 113332
DOI: 10.1016/j.ejmech.2021.113332

Synaptic Dysfunction in Alzheimer’s Disease: Aβ, Tau, and Epigenetic Alterations

Ke Li, Qing Wei, Fang-Fang Liu, Fan Hu, Ao-ji Xie, Ling-Qiang Zhu and Dan Liu

Mol Neurobiol, 2018, 55, 3021
DOI: 10.1007/s12035-017-0533-3

GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia

Meng-yi Xu and Albert H C Wong

Acta Pharmacol Sin, 2018, 39, 733
DOI: 10.1038/aps.2017.172

Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression

Carlos Moreno-Yruela, Daniel M. Fass, Chialin Cheng, Joachim Herz, Christian A. Olsen and Stephen J. Haggarty

ACS Chem. Neurosci., 2019, 10, 3769
DOI: 10.1021/acschemneuro.9b00281

CoREST Complex-Selective Histone Deacetylase Inhibitors Show Prosynaptic Effects and an Improved Safety Profile To Enable Treatment of Synaptopathies

Nathan O. Fuller, Antonella Pirone, Berkley A. Lynch, Michael C. Hewitt, Maria S. Quinton, Timothy D. McKee and Magnus Ivarsson

ACS Chem. Neurosci., 2019, 10, 1729
DOI: 10.1021/acschemneuro.8b00620